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development of autoimmune diseases 
were demonstrated by the example of pri-
mary biliary cirrhosis. The already known 
increased risk in first-degree relatives of 
PBC2 patients and the high concordance in 
monozygotic compared to dizygotic twins 
associated with bacteria, viruses, xenobi-
otics or chemical compounds (e.g., drugs 
like acetaminophen) have the potential 
to modify host proteins to render them 
more immunogenic. Chemical xenobi-
otic modification of the lipoyl domain 
of the E2 component of pyruvate dehy-
drogenase complexes is sufficient to break 
self-tolerance, allowing the production of 
pathognomonic anti-mitochondrial auto-
antibodies.
Elizabeth Jury (London, UK) spoke 
of the importance of regulatory B cells in 
autoimmunity and the interaction between 
these cells and invariant natural killer T 
cells. Systemic lupus erythematosus iNKT3 
PBC = primary biliary cirrhosis
iNKT = invariant natural killer T
t he Medinterna International Meeting took place in Porto, Portugal, on 6–9 
February 2013. This annual conference is 
organized by the Medinterna Association 
and sponsored by São João Hospital 
Centre. Different topics in Autoimmunity 
were discussed over the four days. The 
first day of the meeting, February 6, was 
dedicated to arthritis, specifically rheu-
matoid arthritis cardiovascular risk fac-
tors in RA1, and the relationship between 
bone, cartilage and osteoporosis.
wHat did we learn On  
FeBruarY 7?
Vasculitis was the topic of the day. M. Eric 
Gershwin (Davis, USA) began with a lec-
ture on the relationship between environ-
ment and autoimmunity. The importance 
of this association and the balance between 
genetic and environmental factors in the 
RA = rheumatoid arthritis
cells are numerically and functionally 
impaired because of a decreased expression 
of CD1d on immature B cells. This abnor-
mal interaction was reversed in patients 
responding to rituximab treatment.
Yehuda Shoenfeld (Tel Aviv, Israel), in 
his talk on vaccination and autoimmune 
diseases, summarized the most consistent 
associations between infecting agents and 
autoimmune diseases [Table 1]. As we 
know, several infections can induce the 
production of autoantibodies. He dem-
onstrated that the burden of Epstein-Barr 
virus in peripheral blood mononuclear 
cells was more than 15-fold greater in SLE4 
patients than in healthy control individu-
als; that high levels of anti-Saccharomyces 
cerevisiae (produced after exposure to 
alcoholic beverages, rice, vaccine adju-
vant) were found in 57.5% of patients with 
active SLE vs. 8.5% of healthy controls; that 
Helicobacter pylori eradication raised the 
platelet count in idiopathic thrombocy-
topenic purpura; and that malaria infec-
tions may exert a protective effect against 
autoimmune nephritis in SLE. Finally, 
vaccination with phosphorylcholine com-
pounds was discussed as a future therapy 
for prophylaxis of autoimmune diseases.
In the first roundtable discussion of the 
day, on systemic vasculitis, Cees Kallenberg 
(Groningen, The Netherlands) presented 
identifying risk and predictive factors 
in ANCA-associated vasculitis. Silica, 
some drugs such as propylthiouracil, and 
Staphylococcus aureus nasal carriage were 
identified as risk factors, while PR3 and per-
sistence of ANCA after induction were con-
SLE = systemic lupus erythematosus
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1. Epstein-Barr virus (MS, SLE, RA, Sjögren’s syndrome)
2. Cytomegalovirus (SLE, atherosclerosis, diabetes mellitus, systemic sclerosis, IBD)
3. Helicobacter pylori (ITP, SSc, Crohn’s disease, GBS)
4. Chlamydia pneumoniae (atherosclerosis, MS)
5. Parvovirus B19 (SSc?)
6. Escherichia coli (RA)
7. Proteus mirabilis (RA)
8. Yersinia enterocolitica (IBD)
9. Campylobacter jejuni (GBS)
table 1. Most consistent associations between infecting agents and autoimmune diseases
MS = multiple sclerosis, SLE = systemic lupus erythematosus, RA = rheumatoid arthritis,  
IBD = inflammatory bowel disease, ITP = idiopathic thrombocytopenic purpura,  
SSc = systemic sclerosis, GBS = Guillain-Barre syndrome
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sidered predictive factors for relapsing dis-
ease. The new classification of vasculitis was 
also discussed. Lisa Willcocks (Cambridge, 
UK) presented a brief review on vasculitis 
treatment (current and new therapies). For 
induction, intravenous pulse cyclophos-
phamide was shown to induce remission, 
as did a daily oral regimen with fewer side 
effects; for maintenance, azathioprine was 
shown to be superior to mycophenolate 
mofetil. Rituximab treatment in vasculitis 
(RITUXIVAS and RAVE) was also effec-
tive as an alternative to cyclophosphamide 
mainly in refractory disease. Remission was 
achieved in a higher percentage when ritux-
imab was administered every 6 months for 
2 years. Jan Willem Tervaert (Maastricht, 
The Netherlands) spoke about vasculitis 
complications, particularly increased car-
diovascular risk. Accelerated atherosclerosis 
in large vessel vasculitis is well documented, 
and it was found that the criteria for meta-
bolic syndrome in small vessel vasculitis 
were met by a higher number of patients 
compared to healthy controls. These find-
ings could be associated with therapy 
(steroids in high doses – prednisolone or 
equivalent > 7.5 mg/day; B cell depletion) 
and high myeloperoxidase levels. In large 
vessel vasculitis, preventive treatment with 
low dose aspirin was encouraged and it was 
demonstrated that the use of statins will 
likely be effective in reducing cardiovascu-
lar risk. The need for randomized control 
trials was reinforced. 
The subject of the second roundtable 
discussion was idiopathic inflammatory 
myopathies. Ingrid Lundberg (Stockholm, 
Sweden) highlighted the importance of 
CD28null T cell, Jo-1 and high mobil-
ity group chromosomal protein 1 in the 
inflammation of muscles. Some of them 
may be potential targets for therapy. Hasha 
Gunawardena (Bristol, UK) spoke of the 
clinical relevance of and differences between 
the specific and non-specific autoantibod-
ies in idiopathic inflammatory myopathies 
[Figure 1]. Finally, Jiri Vencovsky (Prague, 
Czech Republic) reviewed current treat-
ments. Glucocorticoids remain the first 
choice (1 mg/kg/day); if effective, start a 
gradual reduction after 4 weeks, if not, 
check the diagnosis and add immunosup-
pressive drugs (methotrexate or azathio-
prine). In refractory disease rituximab may 
be effective, intravenous immunoglobulin 
has mixed results, and anti-tumor necrosis 
factor therapy is not recommended.
In the roundtable on hepatobiliary and 
pancreatic autoimmune disorders, Diego 
Vergani (London, UK) led a discussion on 
the basic science of autoimmune hepa- 
titis. Susana Lopes (Porto, Portugal) 
showed that hepatobiliary involvement in 
inflammatory bowel disease (more com-
monly primary sclerosing cholangitis and 
autoimmune hepatitis) do not correlate 
with disease activity. It was also reinforced 
that some drugs used in their treatment 
(e.g., anti-TNFα5 agents) could induce 
autoimmune hepatitis. Pedro Pereira 
(Porto, Portugal) distinguished between 
the two subtypes of autoimmune pancre-
atitis and reviewed the HISORt criteria 
and the therapeutic options in these dis-
eases. Steroids are the main therapy, with 
azathioprine and rituximab being used in 
refractory disease (20%–40%).
TNFα = tumor necrosis factor-alpha
After Ducla Soares (Lisbon, Portugal) 
lectured on the interaction between the 
autonomic nervous system and autoim-
munity, David D’Cruz (London, UK) pre-
sented a review on relapsing polycondritis. 
The diagnosis of this disease requires two 
major criteria (auricular chondritis, nasal 
chondritis, laryngotracheal chondritis) or 
one major plus two minor criteria (ocular 
symptoms, hearing loss, vertigo, seronega-
tive polyarthritis). The first clinical assess-
ment is based on an otolaryngological, 
ophthalmological, cardiovascular and pul-
monary evaluation (pulmonary function 
tests and dynamic inspiratory/expiratory 
computed tomography examination). Since 
no randomized control trials have been 
published, it was proposed that non-steroi-
dal anti-inflammatory drugs, colchicine, 
dapsone, inhaled or topical steroids be used 
for mild disease; that steroids and immuno-
suppressive drugs (rituximab, azathioprine, 
mycophenolate mofetil, cyclosporin) be 
used for moderate disease; and intravenous 
methylprednisolone, intravenous cyclo-
phosphamide, IVIG6 and plasma exchange 
for severe disease (life-threatening). 
IVIG = intravenous immunoglobulin
Figure 1. Autoantibodies in idiopathic inflammatory myopathies
DM = diabetes mellitus
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The day finished with a very interesting 
case report presented by Marco Alba and 
Gerard Espinosa (Barcelona, Spain) describ-
ing mixed cryoglobulinemia. Conventional 
immunosuppressive therapy was used with-
out response. A small B cell clone was later 
identified allowing the experimental and 
successful use of bortezomib.
wHat did we learn On  
FeBruarY 8?
Srini Kaveri took us on a time travel 
through the history of IVIG. He described 
the many theories developed over the years 
to explain the mechanism of IVIG, from 
the Fc receptor blockade in the 1980s, to 
the idiotypy theory, the cytokine network 
in the 1990s and the Th1/Th2 balance 
theory in the late 1990s. Subsequent papers 
theorized that IVIG also could influence 
dendritic cells and T regulatory cells. 
Although much has been written, there is 
still much to discover about IVIG.
Jan Damoiseaux and Jan Tervaaet 
(Maastricht) talked about cryoglobuline-
mia, reminding us that this possible diag-
nosis should always be suspected and that 
it is mostly associated with hepatitis C virus 
infection, although there are exceptions. 
We also learned that while corticosteroids 
are the main treatment, there are promising 
results with rituximab and interleukin-2.
The scientific program moved on with 
Athol Wells (London, UK) who spoke 
about lung involvement in systemic sclero-
sis.  Since this is the most common cause of 
death in this condition, severity staging is 
crucial, although there are as yet no perfect 
tools. When assessing a patient and when 
in doubt as to the severity of the disease, 
one should treat vigorously using immuno-
suppression to prevent progression.
Luc Mouthon (Paris, France) spoke of 
scleroderma renal crisis, which is associ-
ated with high mortality. It is mainly a 
clinical diagnosis, so a renal biopsy is not 
mandatory. He spoke of the role of cortico-
steroids in inducing this condition and that 
the prior use of angiotensin-converting 
enzyme inhibitors may be associated with 
higher mortality in patients who actually 
develop SRC7. The search for new therapeu-
tic targets continues. Recent papers indi-
cate that endothelin 1 may be an answer 
as it was found to be overexpressed in 
glomeruli and arterioles in SRC.
Maria José Leandro (London, UK) then 
discussed IL-68 inhibition as a treatment 
for rheumatoid arthritis. Tocilizumab 
is indicated when there is inadequate 
response or intolerance to disease-
modifying anti-rheumatic drugs or TNF 
antagonists. It can be used in both mono-
therapy and combination therapy. Studies 
have also shown tocilizumab to be more 
effective than adalimumab monotherapy. 
This IL-6 inhibitor has been shown to 
arrest progression of structural damage 
and improve quality of life after 24 weeks 
of treatment.
Gerry Coghlan (London) spoke about 
pulmonary hypertension in systemic scle-
rosis, reporting that survival has improved 
but that pulmonary arterial hypertension 
must be recognized in our patients. Newer 
and more sensitive tools are emerging to 
improve the diagnosis.
The next subject was vaccination, with 
David Fedson (SergyHaut, France) speak-
ing on anti-pneumococcal vaccination 
and its vital role in reducing pneumococ-
cal invasive disease. Pneumococcal disease 
is still an important health problem for 
older adults and the vaccine has proven to 
be clinically and cost-effective in reducing 
severity and rate. It has been shown that 
the antibody response to polysaccharide 
pneumococcal vaccination, protecting 
against invasive disease, may last up to 
10 years. Much work has still to be done 
but one must “celebrate the extraordinary 
progress that has already been made in the 
control of pneumococcal infection with 
vaccination.” 
Saraiva da Cunha (Coimbra, Portugal) 
spoke about herpes zoster infection, a fre-
quent infection in older adults, with post-
herpetic neuralgia as its most common 
complication. The herpes zoster vaccine 
is now used to reduce severity of disease 
and occurrence of post-herpetic neural-
SRC = scleroderma renal crisis
IL = interleukin
gia and is recommended for people over 
age 50 years. Many questions have still to 
be answered with regard to the optimal 
timing for vaccination or the duration of 
the antibody response, but some vaccina-
tion protocols for rheumatoid arthritis 
and inflammatory bowel disease already 
mention this option. It is hoped that it will 
be recommended for other autoimmune 
diseases.
The day went on with Dr. Isabel Almeida 
and Dr. Ivone Silva (both from Porto) dem-
onstrating the burden of digital ulcers in 
scleroderma that lead to a high degree of 
disability and high risk of recurrence. It was 
also claimed that effective prevention is the 
best treatment and that lifestyle modifica-
tions as well as pharmacological treatment 
are essential.
Carmen Siméon, from Barcelona, then 
spoke of the need for pre-scleroderma 
classification criteria as a way to increase 
early diagnosis. A high degree of suspicion 
is necessary when a patient presents with 
Raynaud phenomenon, puffy fingers and 
antinuclear antibody – “red flags” for early 
scleroderma. Dr. Siméon also spoke of the 
importance of a thorough patient screen-
ing program in order to diagnose internal 
organ involvement early. Therefore, all 
patients with suspected early scleroderma 
must complete an esophageal manometry, 
echocardiogram and lung function tests.
The theme of systemic sclerosis 
continued with Carles Tolosa Vilella 
(also from Barcelona) who reviewed the 
therapeutic tools available. For the cuta-
neous lesions, recent studies have shown 
that MMF9 and rituximab are promis-
ing. As for interstitial lung disease, the 
progression and severity of the illness 
must dictate therapeutic choice – thus, 
in induction therapy, cyclophospha-
mide may be used in severe disease and 
MMF in moderate disease; maintenance 
therapy may use MMF or azathioprine 
and in refractory therapy rituximab can 
be used. In digestive disease only symp-
tomatic treatment should be given, such 
as proton pump inhibitors or prokinetics. 
MMF = mycophenolate mophetil 
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A patient with Raynaud phenomenon 
and/or digital ulcers may use calcium 
channel blockers, prostacyclins, endo-
thelin inhibitors and phosphodiesterase 
inhibitors, as well as undertaking lifestyle 
modifications and preventive measures. 
In pulmonary hypertension immuno-
suppressants are usually not required, 
patients being treated with calcium chan-
nel blockers if vasoreactivity is present, or 
prostacyclins, endothelin inhibitors and 
phosphodiesterase inhibitors if there is 
no vasoreactivity. In scleroderma renal 
crisis, angiotensin-converting enzyme 
inhibitors should be titrated and, if 
needed, calcium channel blockers or 
alpha-blockers added. In extremis, dyali-
sis must be initiated.
Carlos Selmi (Milan, Italy) ended the 
day with a session on Epigenetics in Auto- 
immunity. He demonstrated that DNA 
methylation determines gene expression 
and that such methylation is affected 
by environmental factors. His work on 
monozygotic twins thus showed that these 
twins are discordant in the frequency of 
autoimmune diseases, which may be 
attributed to differences in DNA methyla-
tion in several genes. The fact that certain 
autoimmune diseases have a geographical 
distribution also shows that the environ-
ment can affect gene expression.
Finally, on February 9, the last day of 
the meeting, we heard several lectures 
dedicated to antiphospholipid syndrome. 
In particular, the problems related to preg-
nancy and APS10 (by Monika Ostensen), the 
mechanisms of thrombosis in APS (Anisur 
Rahman), and the difficulties diagnosing 
seronegative APS (Roger Lévy, from Brazil).
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APS = antiphospholipid syndrome
 Fibroblasts are the major mesenchymal cell type in 
connective tissue and deposit the collagen and elastic 
fibers of the extracellular matrix (ECM). Even within a single 
tissue, fibroblasts exhibit considerable functional diversity, 
but it is not known whether this reflects the existence of 
a differentiation hierarchy or is a response to different 
environmental factors. Using transplantation assays 
and lineage tracing in mice, Driskell and co-researchers 
show that the fibroblasts of skin connective tissue arise 
from two distinct lineages. One forms the upper dermis, 
including the dermal papilla that regulates hair growth 
and the arrector pili muscle, which controls piloerection. 
The other forms the lower dermis, including the reticular 
fibroblasts that synthesize the bulk of the fibrillar ECM, 
and the pre-adipocytes and adipocytes of the hypodermis. 
The upper lineage is required for hair follicle formation. 
In wounded adult skin, the initial wave of dermal repair is 
mediated by the lower lineage and upper dermal fibroblasts 
are recruited only during re-epithelialization. Epidermal 
β-catenin activation stimulates the expansion of the upper 
dermal lineage, rendering wounds permissive for hair follicle 
formation. These findings explain why wounding is linked to 
formation of ECM-rich scar tissue that lacks hair follicles. 
They also form a platform for discovering fibroblast lineages 
in other tissues and for examining fibroblast changes in 
aging and disease.
Nature 2013; 504: 277
Eitan Israeli
capsule
distinct fibroblast lineages determine dermal architecture in skin development and repair
Tumor recurrence represents a major clinical challenge. Kottke 
et al. show that emergent recurrent tumors acquire a phenotype 
radically different from that of their originating primary tumors. 
This phenotype allows them to evade a host-derived innate 
immune response elicited by the progression from minimal 
residual disease (MRD) to actively growing recurrence. 
Screening for this innate response predicted accurately in 
which mice recurrence would occur. Premature induction of 
recurrence resensitized MRD to the primary therapy, suggesting 
a possible paradigm shift for clinical treatment of dormant 
disease in which the current expectant approach is replaced 
with active attempts to uncover MRD before evolution of the 
escape phenotype is complete. By combining screening with 
second-line treatments targeting innate insensitivity, up 
to 100% of mice that would have otherwise relapsed were 
cured. These data may open new avenues for early detection 
and appropriately timed, highly targeted treatment of tumor 
recurrence irrespective of tumor type or frontline treatment. 
Nature Med 2013; 19: 1625
Eitan Israeli
capsule
detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence
“what i like in a good author isn’t what he says, but what he whispers”
Logan Pearsall Smith (1865-1946), American-born British essayist and critic 
